长效β_2受体激动剂Salmeterol对哮喘峰呼气流速的影响

Effect of Salmeterol on Peak Expiratory Flow in Patients with Asthma

选择４０例哮喘病人，实验组（２０例）给予Ｓａｌｍｅｔｅｒｏｌ（施立稳）５０μｇ日２次吸入，对照组（２０例）给予Ｐｒｏｃａｔｅｒｏｌ（美喘清）５０μｇ日２次口服。疗程４周，随访２周。以用药前后ＰＥＦ、ＦＥＶ１、ＦＶＣ变化为观察指标。结果，实验组用药２周肺功能即有改善，清晨ＰＥＦ显著提高（Ｐ＜０．０５）。用药４周时改变最明显（Ｐ＜０．０１）。对照组用药后清晨ＰＥＦ稍有提高，但与用药前相比差别不显著。Ｓａｌｍｅｔｅｒｏｌ可明显提高清晨ＰＥＦ，睡前常规吸入可控制夜间哮喘发作。实验组停药２周肺功能仍保持在基础水平之上，可能与其抗炎作用有关。

Forty patients with asthma were randomly assingned into experimental or control group, each had 20 subjects. Salmeterol was administered via a diskhaler with the dosage of 50 μg q.12 h in the former, and Procaterol was taken 50 μg orally twice a day in the latter. The treatment went on at three stages:1 week for running in, 4 weeks for therapy and 2 weeks for following up. All patients were provided with dry powder of salbutamol when necessary throughout the study. We observed the changes of PEF,FEV 1 and FVC before and after treatment. The lung function improved in experimental group after 2 weeks of therapy. The morning PEF increased from 274.5 L/min to 309.25L/min (P<0.05) and FEV 1 from 1.75 L to 1.90 L. Lung function bettered significantly after 4 weeks of the process. Morning PEF increased up to 311.00L/min (P<0.01) and FEV 1 up to 2.16 L(P<0.01). The alteration of lung function in the control group was not so favorable. Salmeterol could markedly increase morning PEF and its bronchial dilatation effect could last at least for 12 hours. Therefore it was beneficial for preventing the attack of nocturnal asthma. The level of lung function in experimental group was above basic value even after two week cessation of therapy. The morning PEF reached 302 L/min (P< 0.05). This might be related to the potential antiinflammatory action of Salmeterol.